Damora Therapeutics, Inc. (NasdaqCM: DMRA)
Health Care · Biotechnology · US
$21.08
+2.08% today · +65.3% 1Y
Damora Therapeutics, Inc. (NasdaqCM: DMRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.30B and employs 7 people.
Over the last twelve months the share price has gained 65.3%, trading between 4.95 and 38.33.
Tweenvest scores Damora Therapeutics, Inc. across four factors: quality 37/100, value 91/100. Its strongest factor is value.
DMRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.30B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -9.88
- Dividend yield
- —
- Beta (5Y)
- 1.44
- 52-week high
- $38.33
- 52-week low
- $4.95
- Avg volume (3M)
- —
- Shares outstanding
- 61.74M
- Employees
- 7
- Next earnings
- —
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- ISIN
- KYG2646Y1044
- Founded
- 2011
- Listed since
- Oct 29, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GNI Group Ltd.TSE: 2160 | $1.33B | ¥3,200.00 | -3.18% |
| Biotest GmbH & Co. KGaAHMSE: BIO0 | $1.33B | €30.00 | -9.64% |
| Everest Medicines LimitedSEHK: 1952 | $1.33B | HK$29.60 | +3.35% |
| Ascentage Pharma Group InternationalSEHK: 6855 | $1.32B | HK$28.22 | -3.36% |
| Liaoning Chengda Biotechnology Co., Ltd.SHSE: 688739 | $1.30B | CN¥21.20 | +0.86% |
| Vcanbio Cell & Gene Engineering Corp., LtdSHSE: 600645 | $1.30B | CN¥19.10 | +2.25% |
| Vitrolife AB (publ)OM: VITR | $1.29B | Skr95.60 | +2.69% |
| Seegene, Inc.KOSDAQ: A096530 | $1.29B | ₩38,150.00 | +3.39% |
Figures last refreshed Oct 11, 2026.